Skip to main content
SpringerLink
Log in
Book cover

Minimal Residual Disease in Acute Leukemia

  • Book
  • © 1984

Overview

Editors:
  1. B. Löwenberg

    1. The Dr Daniël den Hoed Cancer Center, Rotterdam Radio-Therapeutic Institute, Rotterdam, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. A. Hagenbeek

    1. The Dr Daniël den Hoed Cancer Center, Rotterdam Radio-Therapeutic Institute, Rotterdam, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Oncology (DION, volume 19)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (31 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Detection of Minimal Residual Disease in Acute Leukemia

    1. Nucleic Acid Cytometry, Interphase Chromosomes and Nucleolar Antigen in the Detection of Residual Leukemia in Morphologic Remission

      • B. Barlogie, W. N. Hittelman, F. M. Davis, H. Kantarjian
      Pages 1-18

    2. Automated Detection of Rare Hemopoietic Cell Types by Flow Cytometry and Image Analysis

      • J. W. M. Visser
      Pages 19-43

    3. Detection of Minimal Residual Leukemia Utilizing Monoclonal Antibodies and Fluorescence Activated Cell Sorting (FACS)

      • Anton Hagenbeek, Anton C. M. Martens
      Pages 45-54

    4. Discrimination Between Normal Hemopoietic Stem Cells and Myeloid Leukemia Cells Using Monoclonal Antibodies

      • Beverly Lange, Dario Ferrero, Silvana Pessano, Howard Hubbell, Antonio Palumbo, Sun Kai Lai et al.
      Pages 55-65

    5. Detection of Minimal Residual Disease in TdT Positive T Cell Malignancies by Double Immunofluorescence Staining

      • J. J. M. Van Dongen, H. Hooijkaas, K. Hählen, K. Benne, W. M. Bitter, A. A. Van Der Linde-Preesman et al.
      Pages 67-81

    6. Detection of Early Relapse and Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia by Enumeration of Terminal Deoxynucleotidyl Transferase-Positive Cells in Peripheral Blood

      • George R. Buchanan, R. Graham Smith
      Pages 83-95

  3. Treatment of Minimal Residual Disease in Acute Leukemia: Chemotherapy

    1. Principles of Therapy of Malignancy Extrapolated from a Rat Model of Leukemia to Man

      • P. J. Burke
      Pages 97-109

    2. Evaluation and Chemotherapy of Residual Disease in Acute Leukemia

      • R. Zittoun, J. P. Marie
      Pages 111-125

    3. The Treatment of Minimal Residual Disease During Remission in AML

      • R. S. Weiner
      Pages 127-140

    4. Short Term Chemotherapy for Acute Myelogenous Leukaemia

      • T. A. Lister, W. Gregory, A. Z. S. Rohatiner, B. Birkhead, R. Biruls, M. Barnett et al.
      Pages 141-148

    5. Factors Influencing Disease Free Interval after Achieving Complete Remission in Acute Leukemia

      • M. J. Keating
      Pages 149-164

  4. Autologous Bone Marrow Transplantation in the Treatment of Acute Leukemia

    1. In Vitro Chemotherapy as a Prelude to Autologous Marrow Transplantation in Hematologic Malignancy

      • George W. Santos, Herbert Kaizer
      Pages 165-181

    2. In Vivo and in Vitro Pharmacologic Purification of Bone Marrow Contaminated with Tumor Cells Using VP16-213 and Nitrogen Mustard

      • Patrick J. Stiff, Thomas P. U. Wustrow, Alan R. Koester, Michael F. Derisi, Bayard D. Clarkson
      Pages 183-196

    3. AML Cell Heterogeneity. Implications for Leukemia Cell Separation from Autologous Bone Marrow Grafts

      • Bob Löwenberg, Jan Bauman
      Pages 197-207

    4. Elimination of Leukemic Cells from Remission Marrow Suspensions by an Immunomagnetic Procedure

      • Karel A. Dicke, Christopher H. Poynton, Christoher L. Reading
      Pages 209-221

    5. The Use of Immunotoxins to Kill Neoplastic B Cells

      • Ellen S. Vitetta, Jonathan W. Uhr
      Pages 223-232

    6. Monoclonal Antibodies for Purging Bone Marrow of Acute Lymphoblastic Leukemia or Graft Versus Host Producing Cells:Antibody Plus Complement or Immunotoxins

      • J. Kersey, D. Vallera, N. Ramsay, L. Filipovich, R. Stong, T. LeBien et al.
      Pages 233-239

    7. Treatment of Autologous Bone Marrow Grafts with Antibodies Against All Cells

      • S. Thierfelder, B. Netzel, G. Hoffmann-Fezer, B. Kranz, J. Haas
      Pages 241-253

    8. Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia

      • S. E. Sallan, R. C. Bast Jr, J. M. Lipton, J. Ritz
      Pages 255-264
Back to top

Keywords

About this book

The objective of the treatment of acute leukemia involves the eradication of all neoplastic cells, including the last one. Ideally, treatment should be controlled by monitoring cell kill. If the last cells could be discovered and their biological properties be determined, the qualitative and quantitative effects of treatment should be directly evaluable. This should ultimately permit a calculated tumor cell reduction thereby avoiding overtreatment and excessive toxicity and thus providing a basis for individualized antileukemic treatment. In recent years several new developments have contributed to the selective discovery of minimal numbers of leukemic cells which are hidden among the normal cells in the marrow cavities. These methods are the first steps to the realization of the therapeutic goals indicated above. They include the production and ap­ plication of monoclonal antibodies against differentiation antigens on the cell sur­ face, the use of pulse cytophotometry - and cell sorter techniques, the employment of cytogenetics, the development of culture techniques for selective growth of precursor cells and several others. These methodologies offer prospects for refined diagnosis and, as far as the elimination of leukemic cells is concerned, the further development of autologous bone marrow transplantation. Eliminating tumor cells from autologous grafts requires the detailed knowledge of the cellular inter­ relationships within the neoplasm so that the neoplastic cells responsible for tumor propagation are specifically removed. Recognition and characterization of the clonogenic cells of the neoplasm should then lead to determining their sensitivity to the therapeutic agents which are clinically applied.

Editors and Affiliations

  • The Dr Daniël den Hoed Cancer Center, Rotterdam Radio-Therapeutic Institute, Rotterdam, The Netherlands

    B. Löwenberg, A. Hagenbeek

Bibliographic Information

  • Book Title: Minimal Residual Disease in Acute Leukemia

  • Editors: B. Löwenberg, A. Hagenbeek

  • Series Title: Developments in Oncology

  • DOI: https://doi.org/10.1007/978-94-009-5670-4

  • Publisher: Springer Dordrecht

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media Dordrecht 1984

  • Softcover ISBN: 978-94-010-9002-5Published: 28 December 2011

  • eBook ISBN: 978-94-009-5670-4Published: 11 November 2013

  • Edition Number: 1

  • Number of Pages: 416

  • Number of Illustrations: 17 b/w illustrations

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation